STAT3 inhibitors for cancer therapy: Have all roads been explored?
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The signal transducer and activator of transcription STAT3 is a transcription factor which plays a key role in normal cell growth and is constitutively activated in about 70% of solid and hematological cancers. Activated STAT3 is phosphorylated on tyrosine and forms a dimer through phosphotyrosine/src homology 2 (SH2) domain interaction. The dimer enters the nucleus via interaction with importins and binds target genes. Inhibition of STAT3 results in the death of tumor cells, this indicates that it is a valuable target for anticancer strategies; a view that is corroborated by recent findings of activating mutations within the gene. Yet, there is still only a small number of STAT3 direct inhibitors; in addition, the high similarity of STAT3 with STAT1, another STAT family member mostly oriented toward apoptosis, cell death and defense against pathogens, requires that STAT3-inhibitors have no effect on STAT1. Specific STAT3 direct inhibitors consist of SH2 ligands, including G quartet oligodeoxynucleotides (ODN) and small molecules, they induce cell death in tumor cells in which STAT3 is activated. STAT3 can also be inhibited by decoy ODNs (dODN), which bind STAT3 and induce cell death. A specific STAT3 dODN which does not interfere with STAT1-mediated interferon-induced cell death has been designed pointing to the STAT3 DBD as a target for specific inhibition. Comprehensive analysis of this region is in progress in the laboratory to design DBD-targeting STAT3 inhibitors with STAT3/STAT1 discriminating ability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
The SIF binding element confers sis/PDGF inducibility onto the c‐fos promoter.
Wagner, B. J., Hayes, T. E., Hoban, C. J., & Cochran, B. H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07898.x · Cited by 592
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Seidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Stein, R. B., & Rosen, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.3041 · Cited by 415
Reich, N. C., & Liu, L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1885 · Cited by 376
DNA Binding Specificity of Different STAT Proteins
Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., & Bucher, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m001748200 · Cited by 369
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
Cited by
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 271
STAT3, stem cells, cancer stem cells and p63
Galoczova, M., Coates, P., & Vojtesek, B. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-018-0078-0 · Cited by 269
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Metadata
- Authors
- Fagard, R., Metelev, V., Souissi, I., & Baran-Marszak, F.
- Venue
- JAK-STAT
- Publisher
- Informa UK Limited
- Published
- 2013-01
- Volume
- 2
- Issue
- 1
- Pages
- e22882
- ISSN
- 2162-3988 (ISSN-L)
- 2162-3996
- OpenAlex
- W1974714084
- Cited by
- 129
- References
- 19
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STAT3 inhibitors for cancer therapy: Have all roads been explored? https://app.cochat.ai/papers/10.4161/jkst.22882
- The paper
- Fagard, R., Metelev, V., Souissi, I., & Baran-Marszak, F. (2013). STAT3 inhibitors for cancer therapy: Have all roads been explored? JAK-STAT. https://doi.org/10.4161/jkst.22882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.